CLARA D. BLOOMFIELD, M.D., F.A.C.P.; RICHARD D. BRUNNING, M.D.; B. J. KENNEDY, M.D., F.A.C.P.
Erythroleukemia is considered a rare form of acute nonlymphocytic leukemia that is particularly resistant to chemotherapy. We have treated nine adults with erythroleukemia with daunorubicin, 1 mg/kg · day, and prednisone, 60 mg/day, for 5 days. Four (44%) complete remissions and three (33%) partial remissions were obtained. Median duration of remission was 6 months (range, 2 to 16 months). All patients who had received no prior therapy responded. Median duration of survival was 12 months (range, 4 to 27 months). We conclude that the combination of daunorubicin and prednisone may be especially useful in inducing remissions in erythroleukemia and that erythroleukemia is more responsive to chemotherapy than previously realized.
BLOOMFIELD CD, BRUNNING RD, KENNEDY BJ. Daunorubicin-Prednisone Treatment of Erythroleukemia. Ann Intern Med. ;81:746–750. doi: 10.7326/0003-4819-81-6-746
Download citation file:
Published: Ann Intern Med. 1974;81(6):746-750.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use